Intrinsic Imaging Awarded Phase I/II Trial of Novel Cancer Therapy
News Jul 15, 2013
During this trial, Intrinsic Imaging will process all images and evaluate treatment response of the patient’s metastatic cancer.
Intrinsic Imaging, an FDA audited, ISO 9001 and ISO 13485 certified imaging core lab specializing in providing imaging core lab services for clinical trials, announced that it was awarded a multicenter Phase I/II clinical trial designed to evaluate a new therapy to treat patients with metastatic colorectal cancer (mCRC).
This clinical research study utilizes a novel investigational biologic treatment for patients with unresectable liver metastases in patients with colorectal cancer. During this trial, Intrinsic Imaging will process all images and evaluate treatment response of the patient’s metastatic cancer.
“Advances in medical research have created several new options focused on the treatment of metastatic colorectal cancer. There remains, however, significant challenges in achieving long-term survival in those patients with metastatic disease. The continued development and evaluation of novel therapies is necessary to benefit patients suffering from this disease,“ said Dr. Amit Mehta, Chief Medical Officer, Intrinsic Imaging.
Intrinsic Imaging’s team of more than sixty board-certified diagnostic radiologists has sub-specialization in all therapeutic areas including, but not limited to, Oncology, Cardiovascular and Thoracic, Central Nervous System, Gastrointestinal & Genitourinary, Musculoskeletal, and Medical Device. The Intrinsic Oncology team consists of 12 fellowship trained board-certified radiologists, and 8 board-certified interventional radiologists who have in-depth experience in, colorectal, pancreatic, breast, lung, ovarian and prostate cancer, among others.
“Colorectal cancer (CRC) continues to be a global public health problem with over 1 million new cases diagnosed each year. Intrinsic Imaging is dedicated to applying our therapeutic and regulatory expertise throughout this clinical trial towards assisting in the development of a new effective therapy to treat patients with metastatic colorectal cancer,” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE